65,437 trials
Paroxysmal Nocturnal Hemoglobinuria
Primary: Percentage of Participants Who Experienced Free C5-associated BTH — 0 percentage of participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Vaccine Refusal
Primary: Change in Vaccine Hesitancy Scores Pre- and Post-Intervention. — -0.4 units on a scale
Hepatic Impairment
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity ( AUC0-inf ) of Tepotinib — 27500; 26100; 24200 Nanogram*hour per milliliter (ng*h/mL)
Nerve Block · Pain, Postoperative · Pelvic Floor Disorders
Primary: Visual Analog Scores at 7am After Surgery — 29.2; 42.6 score on a scale
Behavioral Economics · Gifts, Financial · Point
Primary: Engagement (Percentage of Daily check-in Activities) — 32.8176; 30.242 percentage of completion
Non-valvular Atrial Fibrillation
Primary: Primary Effectiveness Endpoint — 0 percentage of occurence
Supracondylar Humerus Fracture · Post Operative Wound Infection
Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants
Acquired Immunodeficiency Syndrome · HIV/AIDS · Alcohol Drinking
Primary: Change in Problematic Alcohol Use — -0.95; -1.00 score on a scale
Hypercapnic Respiratory Failure · Chronic Obstructive Pulmonary Disease · Dyspnea
Primary: Rated Perceived Dyspnea [RPD] — 5.4; 5.6; 3.97; 4.54 units on a scale (0-10)
Lung Cancer
Primary: Ordering a Free Radon Test Kit — 9; 29 Participants
Chronic Idiopathic Constipation
Primary: CSBM1 & CSBM2 Success Rate — 64; 33; 37; 17 Participants — p=0.0011
Cocaine-Related Disorders · Anhedonia
Primary: Number of Participants Who Were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy) — 3; 3; 6 Participants
Alzheimer Disease, Early Onset
Primary: Change in Reverse Transcriptase Activity From Baseline to 24 Weeks in Plasma of Study Participants — -0.0074 Enzyme units
Cervical Cancer
Primary: Overall Survival — 11.5; 9.5 Months — p=0.0038